35 results about "Cucurbitacin B" patented technology

The invention discloses a traditional Chinese medicine active extract with temperance function, and a preparation method and application thereof. The main active components in the traditional Chinese medicine active extract with temperance function are cucurbitacin compounds, especially cucurbitacin B and cucurbitacin D. The invention also discloses a preparation method of the active extract, andapplication of the active extract in preparing medicines for treating alcoholic psychosis or medicines with temperance function. The active extract can be added by conventional traditional Chinese medicine preparation methods to prepare any clinical preparation after adding various auxiliary materials and carriers required by preparation of different preparation formulations. The active extract disclosed by the invention is a low-toxicity traditional Chinese medicine extract which can be used for effectively treating alcohol dependence and preparing medicines with abstinence function.

The invention discloses an HPLC (High Performance Liquid Chromatography) method for utilizing a chiral column to separate, identify and prepare a monomer matter from a cucurbitacin mixture. The process conditions of the HPLC method are as follows: the chiral column using an amylose derivative as a solid phase is taken as a chromatographic column; more than two mixtures of isopropanol, alcohol, methyl alcohol, acetonitrile, normal hexane, isohexane, n-pentane, trifluoroacetic acid and glacial acetic acid are taken as mobile phases; and a detection wavelength is 220nm-270nm. The HPLC method provided by the invention is characterized by simple operation, high accuracy and strong specificity. The HPLC method can be used for excellently separating matters, such as cucurbitacin B, iso-cucurbitacin B, dihydro cucurbitacin B, cucurbitacin E, and the like, from the cucurbitacin mixture, can be used for preparing various cucurbitacin monomers from the cucurbitacin mixture and also can be used for accurately measuring contents of cucurbitacin raw materials and various cucurbitacins in a prepared product.

The invention discloses a cucumber exosome-like vesicle containing cucurbitacin B and can be used as an anticancer drug. Cucurbitacin B can be used to inhibit the proliferation of various cancer cells, but its extraction method is complicated and time-consuming. The method of isolating cucumber exosome-like vesicles to obtain cucurbitacin B has the advantages of simple and rapid operation, and the lipid bilayer of exosome-like vesicles, as the natural protective film of cucurbitacin B, can be used for a long time. maintain its stability. Moreover, the presence of the lipid bilayer also increased the uptake rate of cucurbitacin B by cells to a certain extent through the principle of similar compatibility. When acting on adenocarcinoma human alveolar basal epithelial cells (A549 cells), the maximum cell activity inhibition rate of cucumber exosome-like vesicles is twice that of cucurbitacin B standard, and the dosage is lower, which can reduce the toxicity to normal cells It has good anticancer potential and industrialization prospects, and is of great significance in clinical tumor treatment applications.

The invention provides streptomycete (Streptomyces sp.) RW-2 used as a glycosidase producing bacterium and application of the streptomycete in preparing cucurbitacin B during biotransformation of cucurbitacin B-2-O glucoside. A bacterial strain is preserved in China Center for Type Culture Collection, the address of the China Center for Type Culture Collection is Wuhan University in Wuhan, China, the postcode is 430072, the preservation number is CCTCC NO:M2013330, and the preservation date is July 17th, 2013. The streptomycete has the beneficial effects that (1) the streptomycete is a common bacterium in the fermentation industry and is safe to use without toxicity and harms; (2) the nutritional requirements of the streptomycete RW-2 are simple, the growth speed of the streptomycete RW-2 is rapid, and the streptomycete RW-2 is easily cultivated; (3) the glycosidase prepared by the streptomycete RW-2 is extracellular enzyme, thallus is removed by separating the extracellular enzyme to obtain crude enzyme, or the crude enzyme can be used as a biotransformation system after being diluted; (4) after biotransformation treatment on total cucurbitacin extracted from muskmelon pedicel, the cucurbitacin B-2-O glucoside can be almost entirely transformed into the cucurbitacin B, and the content of the cucurbitacin B can be increased by 1-2.7 times.

The invention belongs to the technical field of medicine and discloses novel application of Cucurbitacins, namely novel application of Cucurbitacin B, Cucurbitacin B substances, Cucurbitacin BE and a pharmaceutical composition thereof in a medicine for treating ovarian cancer and improving the quantity of leukocytes of radiotherapy patients. The Cucurbitacin can also be a cucurbitacin B monomer, an isocucurbitacin B monomer, a dihydrocucurbitacin B monomer, a cucurbitacin I monomer, and a cucurbitacin O monomer. The Cucurbitacins or pharmaceutical compositions thereof can be matched with a pharmaceutically acceptable carrier and prepared into a tablet, a capsule, a granule, powder, a plaster, an ointment, an aerosol, a suspension, a syrup, an oral liquid, and an injection, and can also be prepared into special dosage forms such as a liposome, microspheres, nanoparticles and an emulsion for cavity administration, external use, oral administration and injection. The individual administration or the combined treatment can be performed, the administration dosage of the Cucurbitacins is calculated according to the total Cucurbitacins, the dosage for healthy adults is between 0.1 and 5mg / d, the best dosage is between 0.3 and 3mg / d, and the administration is performed for 1 to 4 times.